EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis

Nicole Princic, Kristin A Evans, Chintal H Shah, Krystal Sing, Salomé Juethner, Bob G Schultz

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2024-0205 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Nicole Princic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Merative, Ann Arbor, MI 48108, USA. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized, Patient Acceptance of Health Care, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Hereditary angioedema (HAE) is a rare and chronic genetic condition. Lanadelumab and berotralstat, two plasma kallikrein inhibitors, have both been approved for long-term prophylaxis in patients with HAE; however, real-world data comparing costs and healthcare resource utilization (HCRU) are lacking. Materials & methods: This retrospective study used administrative healthcare insurance claims data (Merative™ MarketScan ® Commercial, Medicare and Early View Research Databases; 1 July 2017–31 July 2023) to identify patients with HAE who initiated lanadelumab or berotralstat and were persistent for ≥18 months or 6 months, respectively. Sex, baseline healthcare costs and baseline number of on-demand treatment/short-term prophylaxis medication claims were used to calculate covariate balancing propensity scores for inverse probability of treatment weighting. Following weighting, outcomes during the 6-month follow-up period in patients receiving berotralstat were compared with those during months 0–6, 7–12 and 13–18 in lanadelumab-treated patients.

Results

Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included. After weighting, more berotralstat-treated patients had an all-cause inpatient admission (berotralstat, 9.4%; lanadelumab, months 0–6, 4.0%, 7–12, 1.8%, months 13–18, 2.0%) and emergency room visit (berotralstat, 21.9%; lanadelumab, months 0–6, 14.0%, 7–12, 8.0%, months 13–18, 17.9%). Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab. On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968). The proportion of lanadelumab-treated patients who reduced dosing frequency was 24.8% during months 7–12 and 21.6% during months 13–18.

Conclusion

Patients with HAE initiating lanadelumab versus berotralstat may require less on-demand and supportive HAE treatments and incur lower treatment-related and total healthcare costs. The ability to reduce lanadelumab dosing frequency after an attack-free period may be key in treatment selection, given the combination of cost savings and lower healthcare resource utilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryAntibodies, Monoclonal, HumanizedPatient Acceptance of Health CareHealth Care CostsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultUnited StatesAged

Stichwörter der Autor:innen

berotralstathealthcare costshealthcare resource utilizationhereditary angioedemalanadelumablong-term prophylaxis

Substanzen

Antibodies, Monoclonal, Humanizedlanadelumab

Autor:innen und Institutionen

  • Merative, Ann Arbor, MI 48108, USA.
  • University of Maryland, Baltimore, MD 21201, USA.
  • Takeda Pharmaceuticals USA, Inc., Lexington, MA 02421, USA.

Zitieren

APA

Princic, N., Evans, K. A., Shah, C. H., Sing, K., Juethner, S., & Schultz, B. G. (2025). Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0205

Vancouver

Princic N, Evans KA, Shah CH, Sing K, Juethner S, Schultz BG. Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0205

BibTeX
@article{Princic2025,
  author = {Princic, Nicole and Evans, Kristin A and Shah, Chintal H and Sing, Krystal and Juethner, Salomé and Schultz, Bob G},
  title = {Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2024-0205}
}
Kostenlos starten →